Gray/White Matter Contrast in Parkinson’s Disease

Gray/white matter contrast (GWC) decreases with aging and has been found to be a useful MRI biomarker in Alzheimer’s disease (AD), but its utility in Parkinson’s disease (PD) patients has not been investigated. The aims of the study were to test whether GWC is sensitive to aging changes in PD patien...

Full description

Bibliographic Details
Main Authors: Carme Uribe, Barbara Segura, Hugo C. Baggio, Alexandra Abos, Anna I. Garcia-Diaz, Anna Campabadal, Maria J. Marti, Francesc Valldeoriola, Yaroslau Compta, Nuria Bargallo, Carme Junque
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-03-01
Series:Frontiers in Aging Neuroscience
Subjects:
Online Access:http://journal.frontiersin.org/article/10.3389/fnagi.2018.00089/full
id doaj-86f5a3d6e2df4b508f583ffa34d8ca16
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Carme Uribe
Barbara Segura
Hugo C. Baggio
Alexandra Abos
Anna I. Garcia-Diaz
Anna Campabadal
Anna Campabadal
Maria J. Marti
Maria J. Marti
Maria J. Marti
Francesc Valldeoriola
Francesc Valldeoriola
Francesc Valldeoriola
Yaroslau Compta
Yaroslau Compta
Yaroslau Compta
Nuria Bargallo
Carme Junque
Carme Junque
Carme Junque
spellingShingle Carme Uribe
Barbara Segura
Hugo C. Baggio
Alexandra Abos
Anna I. Garcia-Diaz
Anna Campabadal
Anna Campabadal
Maria J. Marti
Maria J. Marti
Maria J. Marti
Francesc Valldeoriola
Francesc Valldeoriola
Francesc Valldeoriola
Yaroslau Compta
Yaroslau Compta
Yaroslau Compta
Nuria Bargallo
Carme Junque
Carme Junque
Carme Junque
Gray/White Matter Contrast in Parkinson’s Disease
Frontiers in Aging Neuroscience
Parkinson’s disease
gray/white matter contrast
cortical thickness
aging
magnetic resonance imaging
author_facet Carme Uribe
Barbara Segura
Hugo C. Baggio
Alexandra Abos
Anna I. Garcia-Diaz
Anna Campabadal
Anna Campabadal
Maria J. Marti
Maria J. Marti
Maria J. Marti
Francesc Valldeoriola
Francesc Valldeoriola
Francesc Valldeoriola
Yaroslau Compta
Yaroslau Compta
Yaroslau Compta
Nuria Bargallo
Carme Junque
Carme Junque
Carme Junque
author_sort Carme Uribe
title Gray/White Matter Contrast in Parkinson’s Disease
title_short Gray/White Matter Contrast in Parkinson’s Disease
title_full Gray/White Matter Contrast in Parkinson’s Disease
title_fullStr Gray/White Matter Contrast in Parkinson’s Disease
title_full_unstemmed Gray/White Matter Contrast in Parkinson’s Disease
title_sort gray/white matter contrast in parkinson’s disease
publisher Frontiers Media S.A.
series Frontiers in Aging Neuroscience
issn 1663-4365
publishDate 2018-03-01
description Gray/white matter contrast (GWC) decreases with aging and has been found to be a useful MRI biomarker in Alzheimer’s disease (AD), but its utility in Parkinson’s disease (PD) patients has not been investigated. The aims of the study were to test whether GWC is sensitive to aging changes in PD patients, if PD patients differ from healthy controls (HCs) in GWC, and whether the use of GWC data would improve the sensitivity of cortical thickness analyses to differentiate PD patients from controls. Using T1-weighted structural images, we obtained individual cortical thickness and GWC values from a sample of 90 PD patients and 27 controls. Images were processed with the automated FreeSurfer stream. GWC was computed by dividing the white matter (WM) by the gray matter (GM) values and projecting the ratios onto a common surface. The sample characteristics were: 52 patients and 14 controls were males; mean age of 64.4 ± 10.6 years in PD and 64.7 ± 8.6 years in controls; 8.0 ± 5.6 years of disease evolution; 15.6 ± 9.8 UPDRS; and a range of 1.5–3 in Hoehn and Yahr (H&Y) stage. In both PD and controls we observed significant correlations between GWC and age involving almost the entire cortex. When applying a stringent cluster-forming threshold of p < 0.0001, the correlation between GWC and age also involved the entire cortex in the PD group; in the control group, the correlation was found in the parahippocampal gyrus and widespread frontal and parietal areas. The GWC of PD patients did not differ from controls’, whereas cortical thickness analyses showed thinning in temporal and parietal cortices in the PD group. Cortical thinning remained unchanged after adjusting for GWC. GWC is a very sensitive measure for detecting aging effects, but did not provide additional information over other parameters of atrophy in PD.
topic Parkinson’s disease
gray/white matter contrast
cortical thickness
aging
magnetic resonance imaging
url http://journal.frontiersin.org/article/10.3389/fnagi.2018.00089/full
work_keys_str_mv AT carmeuribe graywhitemattercontrastinparkinsonsdisease
AT barbarasegura graywhitemattercontrastinparkinsonsdisease
AT hugocbaggio graywhitemattercontrastinparkinsonsdisease
AT alexandraabos graywhitemattercontrastinparkinsonsdisease
AT annaigarciadiaz graywhitemattercontrastinparkinsonsdisease
AT annacampabadal graywhitemattercontrastinparkinsonsdisease
AT annacampabadal graywhitemattercontrastinparkinsonsdisease
AT mariajmarti graywhitemattercontrastinparkinsonsdisease
AT mariajmarti graywhitemattercontrastinparkinsonsdisease
AT mariajmarti graywhitemattercontrastinparkinsonsdisease
AT francescvalldeoriola graywhitemattercontrastinparkinsonsdisease
AT francescvalldeoriola graywhitemattercontrastinparkinsonsdisease
AT francescvalldeoriola graywhitemattercontrastinparkinsonsdisease
AT yaroslaucompta graywhitemattercontrastinparkinsonsdisease
AT yaroslaucompta graywhitemattercontrastinparkinsonsdisease
AT yaroslaucompta graywhitemattercontrastinparkinsonsdisease
AT nuriabargallo graywhitemattercontrastinparkinsonsdisease
AT carmejunque graywhitemattercontrastinparkinsonsdisease
AT carmejunque graywhitemattercontrastinparkinsonsdisease
AT carmejunque graywhitemattercontrastinparkinsonsdisease
_version_ 1725194783726501888
spelling doaj-86f5a3d6e2df4b508f583ffa34d8ca162020-11-25T01:05:23ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652018-03-011010.3389/fnagi.2018.00089353755Gray/White Matter Contrast in Parkinson’s DiseaseCarme Uribe0Barbara Segura1Hugo C. Baggio2Alexandra Abos3Anna I. Garcia-Diaz4Anna Campabadal5Anna Campabadal6Maria J. Marti7Maria J. Marti8Maria J. Marti9Francesc Valldeoriola10Francesc Valldeoriola11Francesc Valldeoriola12Yaroslau Compta13Yaroslau Compta14Yaroslau Compta15Nuria Bargallo16Carme Junque17Carme Junque18Carme Junque19Medical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, SpainMedical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, SpainMedical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, SpainMedical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, SpainMedical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, SpainMedical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, SpainInstitute of Biomedical Research August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, SpainInstitute of Biomedical Research August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, SpainCentro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Barcelona, SpainParkinson’s Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institute of Neuroscience, University of Barcelona, Barcelona, SpainInstitute of Biomedical Research August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, SpainCentro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Barcelona, SpainParkinson’s Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institute of Neuroscience, University of Barcelona, Barcelona, SpainInstitute of Biomedical Research August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, SpainCentro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Barcelona, SpainParkinson’s Disease and Movement Disorders Unit, Neurology Service, Hospital Clínic de Barcelona, Institute of Neuroscience, University of Barcelona, Barcelona, SpainCentre de Diagnòstic per la Imatge, Hospital Clínic, Barcelona, SpainMedical Psychology Unit, Department of Medicine, Institute of Neuroscience, University of Barcelona, Barcelona, SpainInstitute of Biomedical Research August Pi i Sunyer (IDIBAPS), Hospital Clinic, Barcelona, SpainCentro de Investigación Biomédica en Red Sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clínic de Barcelona, Barcelona, SpainGray/white matter contrast (GWC) decreases with aging and has been found to be a useful MRI biomarker in Alzheimer’s disease (AD), but its utility in Parkinson’s disease (PD) patients has not been investigated. The aims of the study were to test whether GWC is sensitive to aging changes in PD patients, if PD patients differ from healthy controls (HCs) in GWC, and whether the use of GWC data would improve the sensitivity of cortical thickness analyses to differentiate PD patients from controls. Using T1-weighted structural images, we obtained individual cortical thickness and GWC values from a sample of 90 PD patients and 27 controls. Images were processed with the automated FreeSurfer stream. GWC was computed by dividing the white matter (WM) by the gray matter (GM) values and projecting the ratios onto a common surface. The sample characteristics were: 52 patients and 14 controls were males; mean age of 64.4 ± 10.6 years in PD and 64.7 ± 8.6 years in controls; 8.0 ± 5.6 years of disease evolution; 15.6 ± 9.8 UPDRS; and a range of 1.5–3 in Hoehn and Yahr (H&Y) stage. In both PD and controls we observed significant correlations between GWC and age involving almost the entire cortex. When applying a stringent cluster-forming threshold of p < 0.0001, the correlation between GWC and age also involved the entire cortex in the PD group; in the control group, the correlation was found in the parahippocampal gyrus and widespread frontal and parietal areas. The GWC of PD patients did not differ from controls’, whereas cortical thickness analyses showed thinning in temporal and parietal cortices in the PD group. Cortical thinning remained unchanged after adjusting for GWC. GWC is a very sensitive measure for detecting aging effects, but did not provide additional information over other parameters of atrophy in PD.http://journal.frontiersin.org/article/10.3389/fnagi.2018.00089/fullParkinson’s diseasegray/white matter contrastcortical thicknessagingmagnetic resonance imaging